Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5529970 | 0.85 | ALDH1A1 (0.60) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL9547388 | 0.84 | ALDH1A1 (0.58) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL11518064 | 0.84 | ALDH1A1 (0.58) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL11166347 | 0.84 | ALDH1A1 (0.58) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL6086755 | 0.81 | ALDH1A1 (0.58) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL14605923 | 0.81 | ALDH1A1 (0.55) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL9805552 | 0.81 | ALDH1A1 (0.55) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL10971439 | 0.80 | GAA (0.59) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL6086748 | 0.80 | ALDH1A1 (0.53) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL10457083 | 0.79 | ALDH1A1 (0.49) | ALDH1A1POLBGAAALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0035228-B1 | TETRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND ANTI-ULCER COMPOSITION CONTAINING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-01-02 | — | — | EP | claimed |
| US-4372953-A | Tetrazole derivatives, and anti-ulcer composition containing the same | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1983-02-08 | — | — | US | claimed |
| EP-0035228-A1 | Tetrazole derivatives, process for the preparation thereof, and anti-ulcer composition containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-09 | — | — | EP | claimed |
| US-20170305824-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2017-10-26 | — | — | US | disclosed |
| US-9346799-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICALS AG (CH) | 2016-05-24 | — | — | US | disclosed |
| US-9346799-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICALS AG (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2016-05-05 | — | — | US | disclosed |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2016-05-05 | — | — | US | disclosed |
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-8901293-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2010-03-04 | — | — | US | disclosed |
| WO-2007065288-A2 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| US-5177092-A | Transglutaminase Inhibitors, Anticoagulants | MERCK & CO., INC. (US) | 1993-01-05 | — | — | US | disclosed |
| US-5047416-A | Anticoagulants | MERCK & CO., INC. (US) | 1991-09-10 | — | — | US | disclosed |
| EP-0411894-A2 | Azole compounds and their use as transglutaminase inhibitors | MERCK & CO. INC. (US) | 1991-02-06 | — | — | EP | disclosed |
| EP-0035228-B1 | TETRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND ANTI-ULCER COMPOSITION CONTAINING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-01-02 | — | — | EP | disclosed |
| US-4372953-A | Tetrazole derivatives, and anti-ulcer composition containing the same | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1983-02-08 | — | — | US | disclosed |
| EP-0035228-A1 | Tetrazole derivatives, process for the preparation thereof, and anti-ulcer composition containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-09 | — | — | EP | disclosed |
| EP-0035232-A2 | Method and apparatus for the initial acquisition of synchronization for a station in a TDMA satellite communication network | International Business Machines Corporation (US) | 1981-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | ALDH1A1 2194/4885POLB 316/4885GAA 24/4885 |
| US-20170305824-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | TNF, TNFRSF1A, RIPK1 | ALDH1A1 4840/4885POLB 2287/4885GAA 1670/4885 |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | ALDH1A1 2194/4885POLB 316/4885GAA 24/4885 |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | MGAM, MGAM2, B2M | ALDH1A1 2423/4885POLB 277/4885GAA 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.